Resources Repository
-
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Technology Assessment | Health Outcomes | Preferences/Values | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Science/Technology | North America | Europe -
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
State-Transition | Health Outcomes | Costing Methods | Value of Information | Mathematical Models | Dynamic Transmission | Microsimulation | Calibration/Validation | Dynamic Simulation | Decision Analysis | Infectious Diseases | Health/Medicine -
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Health Outcomes | Costing Methods | Evidence Synthesis | Decision Analysis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Policy/Regulation | Health/Medicine | Global | Graduate | Doctoral | Professional -
EditorialPublication 2021Scientific and Regulatory Challenges in Designing mHealth Interventions
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that …
Scientists looking for innovative ways to deliver health care have long searched for mechanisms that can enable the right intervention to be delivered at the right time. Traditional delivery mechanisms have been limited both to the availability of a provider (e.g., a physician) and the location of care (e.g., a hospital or outpatient clinic). In recent years, however, numerous technological advancements—including wearable devices, mobile technologies, and the widespread development and use of user-friendly smartphone applications—have…
Technology Assessment | Health/Medicine | Science/Technology | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Technology Assessment | Probability/Bayes | Test Performance | Infectious Diseases | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Global | North America -
ReviewPublication 2018Primary & Secondary Prevention Interventions for Cardiovascular Disease in LMIC's
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for …
Motivated by the need for evidence on cardiovascular disease (CVD) interventions offering good value for the money, the authors conducted a systematic review, including 50 studies. Included studies were those that reported full economic evaluations of individual and population-based interventions (pharmacologic and non-pharmacologic), for primary and secondary prevention of CVD among adults in LMIC. The majority of the studies were of modelled evaluations, with significant heterogeneity in methods. Most of the economic evaluations evaluated were…
Health Outcomes | Costing Methods | Evidence Synthesis | Chronic Disease/Risk | Health/Medicine | Global -
GuidelinesWeb Portal 2017iDSI Reference Case for Economic Evaluation
This is a reference case which gives 12 principles to guide the planning, conduct and …
This is a reference case which gives 12 principles to guide the planning, conduct and reporting of health economic evaluations in low- and middle-income countries (LMICs). The International Decision Support Group (iDSI) is a network of health, policy and economic experts. It builds on the approaches of the National Institute for Health and Care Excellence (NICE) in the UK, the Health Intervention and Technology Assessment Program (HITAP) in Thailand and the World Health Organization. iDSI…
Health Outcomes | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine | Global -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Health Outcomes | Preferences/Values | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | North America | Europe -
ReviewPublication 2017Model-Based Economic Evaluation of Treatments for Depression: A Systematic Review
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies …
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies evaluating the cost-effectiveness of treatments for depression and examine the appropriateness of different modelling technique for simulating the natural course of depression. The review yielded 41 model-based studies, of which 21 used decision trees (DTs), 15 used cohort-based state-transition Markov models (CMMs), two used individual-based state-transition models (ISMs), and three used discrete-event simulation (DES) models. Just over half of the…
State-Transition | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Mental Health | Health/Medicine